Le Lézard
Classified in: Health
Subjects: PDT, TDS, FVT

Glooko's diasend Diabetes Data Platform to Unveil Greater Connectivity and System Enhancements at EASD Meeting in Barcelona

New third-party app connections, more compatible devices and in-clinic Bluetooth uploads to better connect patients and their data with clinicians

MOUNTAIN VIEW, California and GOTHENBURG, Sweden, Sept. 17, 2019 /PRNewswire/ -- Glooko®, the leader in diabetes data management solutions, continues to strengthen its global position with the introduction of several new features and expanded connectivity capabilities for the diasend® by Glooko system at this week's 55th annual meeting of the European Association for the Study of Diabetes (EASD). The additional device integration partnerships, new ways to upload patient data in clinic, and feature enhancements will be unveiled at the September 17-20 meeting in Barcelona.

Increased device compatibility

At EASD, Europe's largest and most prominent diabetes meeting, Glooko will share new device integrations it has developed with two new partners:

Additional ways to upload data in-clinic

At the beginning of 2019, NFC connectivity (near-field communication) was introduced in the hardware of the diasend® by Glooko system, which serves as a "one-stop shop" for patients when visiting their health care provider, because it's able to upload data from numerous devices regardless of brand. Now, BLE (Bluetooth Low Energy) is also added to the mix of ways to upload data to the diasend® solution, providing greater flexibility for the upload process and making clinic/patient interaction even easier. Both NFC and BLE are expected to become increasingly common in diabetes devices during the next couple of years.

"Glooko is pleased to bring additional value to our customers with new data solutions and device integrations on our trusted diasend data management platform," said Russ Johannesson, CEO of Glooko. "It exemplifies the increasing momentum of Glooko solutions, which provide comprehensive patient-based diabetes data to physicians, better connecting them with their patients. Our greater reach with diasend by Glooko enables healthcare professionals to better focus on value-based outcomes for the patients they serve."

Prominent speakers at EASD

On the scientific front, Glooko will offer in-booth presentations from two renowned speakers:

"We are proud of the array of diasend by Glooko news that will be showcased at EASD this year, and how it highlights our continuous innovation. We are adding more options to our comprehensive list of compatible devices and introducing new ways for them to function seamlessly with our universal solution," said Anders Sonesson, Global VP and General Manager of Glooko.  "As always, we put our users at the heart of everything we do, and these additions will facilitate the patient/clinic interaction from both sides."

*Available in selected European countries.

About Glooko
Glooko's universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world's leaders in diabetes care, our solutions cover more than 2.2 million people with diabetes and are used in 9,000+ clinic locations in 24 countries across 15 languages. Learn more by visiting www.glooko.com 

Media Contacts:

Sebastian Persson
Marketing Director EMEA/APAC
+46 701 46 10 10

Jeff Christensen
SignalWest Public Relations
+1 831-566-0275


These press releases may also interest you

at 18:55
Resverlogix Corp. ("Resverlogix" or the "Company") is pleased to announce the Company will host a Corporate Update Conference Call and Webcast on June 10th, 2020 at 9 am MT/11 am ET. The Company also announces its participation at the 57th ERA-EDTA...

at 18:10
TALTZ® (ixekizumab) demonstrated consistent efficacy and long-term potential to help patients with psoriatic arthritis (PsA) in new data presented virtually today at the European Congress of Rheumatology 2020 (EULAR). Eli Lilly and Company shared...

at 17:47
The U.S. Food and Drug Administration today continued to take action in the ongoing response to the COVID-19 pandemic: The FDA issued an updated FDA COVID-19 Response At-A-Glance Summary that provides a quick look at facts, figures and highlights of...

at 17:30
The "Bioresorbable Medical Material Market to 2027 - Global Analysis and Forecasts by Product Type; Application, and Geography" report has been added to ResearchAndMarkets.com's offering. The bioresorbable medical material market was valued at US$...

at 17:26
The healthcare system in the Commonwealth of Dominica was not strained by the pandemic, with the government managing to contain the spread of the virus from the onset, recording zero deaths and only 16 fully recovered cases. Nonetheless, the...

at 17:25
Since the week of March 12, the Ontario Health Coalition has been tracking all people who have been infected with COVID-19 in outbreaks in health care settings including hospitals, long-term care, retirement homes, public health units, clinics and...

News published on 17 september 2019 at 01:34 and distributed by: